Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China

Journal of Public Health

Volumn 34, Issue 1, 2012, Pages 24-31

  Hser, Y ^a   Du, J ^b   Li, J ^c   Zhao, M ^b   Chang, Y J ^a   Peng, C Y ^a   Evans, E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Yunnan Institute on Drug Abuse   (China)

Author keywords

communicable diseases; health services; public health

Indexed keywords

METHADONE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; ATTITUDE TO HEALTH; CHINA; DISEASE TRANSMISSION; EPIDEMIOLOGY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOLATION AND PURIFICATION; MALE; REGRESSION ANALYSIS; RISK FACTOR; SEROLOGY; SEXUAL BEHAVIOR; SUBSTANCE ABUSE;

ADULT; ANALYSIS OF VARIANCE; CHINA; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; METHADONE; REGRESSION ANALYSIS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84863277196     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdr098     Document Type: Article

References (26)

1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18(5):352-8. (Pubitemid 47374507)
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5(9):558-67.
3. Xia X, Luo J, Bai J et al. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008;122(10):990-1003.
4. World Health Organization (WHO). Hepatitis C. Fact sheet No 164. Geneva, Switzerland: WHO, 2000. www.who.int/inf-fs/en/fact164.html (10 September 2010, date last accessed).
5. Garter RJ, Lai S, Zhang J et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol 2004;33(1):182-8. (Pubitemid 38500175)
6. State Council AIDS Working Committee Office, UN Theme Group on AIDS in China. A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China. Beijing, China: State Council AIDS Working Committee Office, 2006.
7. Wu Z, Sullivan SG, Wang Y et al. Evolution of China's response to HIV/AIDS. Lancet 2007;369(9562):679-90.
8. Bao Y-P, Liu Z-M, Lu L. Systematic review of HIV and HCV infection among drug users in china. Int J STD AIDS 2009;20:399-405.
9. World Health Organization (WHO). A Strategy To Halt and Reverse the HIV Epidemic among People Who Inject Drugs in Asia and the Pacific 2010-2015. Geneva, Switzerland: WHO Press. http://www.searo.who.int/LinkFiles/Publications- Harm-Reduction-Strategy2010-2015.pdf (10 September 2010, date last accessed).
10. National Narcotic Control Commission. The registered drug users in China reach 1.33 million at 2009. http://www.mps.gov.cn/n16/n1252/n1897/n2872/2327636. html.
11. Hagan H, Campbell JV, Thiede H et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006;121(6):710-19.
12. Kwiatkowski CF, Corsi KF, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction 2002;97:1289-94.
13. Heimer R, Clair S, Grau LE et al. Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. Addiction 2002;97(10):1277-87.
14. Strauss SM, Astone-Twerell J, Munoz-Plaza CE et al. Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Serv Res 2007;7:39.
15. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001;61(3):211-5. (Pubitemid 32119301)
16. O'Brien S, Day C, Black E et al. Injecting drug users' understanding of hepatitis C. Addict Behav 2008;33:1602-5.
17. Ruan YH, Hong KX, Liu SZ et al. Community-based survey of HCV and HIV co-infection in injection drug abusers in Sichuan Province of China. World J Gastroenterol 2004;10:1589-93.
18. Lee KC, Lim WW, Lee SS. High prevalence of HCV in a cohort of injectors on methadone substitution treatment. J Clin Virol 2008;41(4):297-300.
19. Hser YI, Li J, Jiang H et al. Effects of a randomized contingency management intervention on opiate abstinence and retention in methadone maintenance treatment in China. Addiction 2011;106(10): 1801-09.
20. Darke S, Hall W, Heather N et al. The reliability and validity of a scale to measure HIV risk taking behavior among intravenous drug users. AIDS 1991;5:181-5.
21. Weatherby NL, Needle R, Cesari H et al. Validity of self-reported drug use among injection drug users and crack cocaine users recruited through street outreach. Eval Program Plann 1994;17:347-55.
22. Needle R, Fisher DG, Weatherby N et al. Reliability of self-reported HIV risk behaviors of drug users. Psychol Addict Behav 1995;9(4):242-50.
23. Strauss SM, Astone-Twerell JM, Munoz-Plaza C et al. Hepatitis C knowledge among staff in U.S. drug treatment programs. J Drug Educ 2006;36(2):141-58.
24. Schwartz RP, Kelly SM, O'Grady KE et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict 2008;17(5):396-401.
25. Brown BS, Jansen DR, Benn GJ. Changes in attitude toward methadone. Arch Gen Psychiatry 1975;32(2):214-8.
26. Du J, Jiang H, Meng YY et al. A mixed methods approach to understanding barriers and facilitators to HIV services utilization among injection drug users in Shanghai, China (manuscript is under review).